Abstract Background: Classical Hodgkin lymphoma (cHL) is a unique lymphoid malignancy
with a tumor microenvironment (TME) consisting of a small number of neoplastic—Hodgkin …

While up to 80% of patients with Hodgkin's lymphoma (HL) are cured with first-line therapy,
relapsed/refractory (R/R) disease remains a clinical challenge and is fatal for many young …

Simple Summary Hodgkin lymphoma accounts for 10% of new lymphoma diagnoses and
has generally high cure rates, although there is a need for new treatments in the relapsed …

Classic Hodgkin lymphoma (cHL) is a tumor composed of rare, atypical, germinal center–
derived B cells (Hodgkin Reed-Sternberg [HRS] cells) embedded within a robust but …

Classical Hodgkin lymphoma (cHL) is characterized by a small number of neoplastic cells in
a background of reactive cells. Children and adults differ in constitution and functionality of …

Classical Hodgkin Lymphoma (cHL) is a B-cell malignancy that, typically, responds well to
standard therapies. However, patients who relapse after standard regimens or are refractory …

Simple Summary The extracellular matrix surrounding or infiltrating tumor tissues, tumor
cells, endothelial cells, immune cells, fibroblasts, macrophages, as well as soluble …

Macrophages have been implicated in the pathogenesis of classical Hodgkin lymphoma
(cHL) and have been suggested to have a negative impact on outcome. Most studies …

Classical Hodgkin's lymphoma accounts for approximately 10% of all malignant lymphomas.
Although most patients can be cured with modern treatment strategies, approximately 25 …

Classical Hodgkin's lymphoma (cHL), a distinct disease entity with characteristic clinical and
pathological features, accounts for approximately 10% of all malignant lymphomas. cHL can …